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Introduction
The international consensus for treatment of small 
cell lung cancer (SCLC) involves platinum doublet 
chemotherapy, however, the optimal duration of this (4 
or 6 cycles) remains unclear, especially for extensive stage 
(ED-SCLC) (1-4). Thoracic radiotherapy is an adjunct 
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to chemotherapy and evidence suggests that a shorter 
time to chemo-radiation improves survival, especially for 
limited stage (LD-SCLC) (5,6). Indeed, for individuals with 
LD-SCLC and performance status (PS) 0-1, concurrent 
thoracic radiotherapy is recommended within the first 2 
chemotherapy cycles. Sequential consolidative thoracic 
radiotherapy is recommended for patients that have shown 
response to chemotherapy who are unfit for concurrent 
irradiation or have ED-SCLC, but the evidence base 
outside of clinical trials is sparse. Prophylactic cranial 
irradiation (PCI) is reserved for people whose cancer has 
not progressed following first line treatment, however its 
efficacy in chemotherapy responders with ED-SCLC has 
been refuted by a recent phase III randomised control 
trial (7). This has prompted the National Institute for 
health and Care Excellence (NICE) to downgrade 
the recommendation from “offer” to “consider” (8). 
The aforementioned therapies are often confined to 
specialist cancer hospitals and hence there are likely to be 
geographical variations in their use (9). 
Patients with ED-SCLC are often symptomatic at 
diagnosis. However, the side effects of treatment and the 
time spent in hospital may pose a significant burden which 
can lower the limited quality and quantity of life they have. 
Therefore, it is important that individuals are offered 
appropriate treatment with a realistic understanding of 
the survival gains. Hence, the objectives of this study were 
to: (I) Quantify the patient, treatment and hospital factors 
associated with 1-year survival in all people diagnosed 
with SCLC. (II) Determine whether 6 in comparison to 
4 chemotherapy cycles, thoracic radiotherapy and PCI 
augment the odds of 1-year survival for individuals who 
receive chemotherapy. We present the following article in 




This study was a retrospective analysis of prospectively 
collected observational cohort data from individuals who 
were diagnosed with SCLC. The study was conducted in 
accordance with the declaration of Helsinki (as revised in 
2013). We performed a statistical analysis of patient, tumour 
and treatment factors to assess their impact on 1-year 
survival in all people diagnosed with SCLC and a sub-
analysis in those who received chemotherapy. The details of 
this analysis are outlined below. 
Study population
This was a retrospective cohort study that used English 
National Lung Cancer Audit (NLCA) data to identify 
people diagnosed with SCLC from 1st January 2015 to 21st 
September 2016 based on their histological code. We linked 
these data with Systemic Anti-Cancer Therapies (SACT), 
National RadioTherapy DataSet (RTDS) and Hospital 
Episode Statistics (HES) data. All were prospectively 
collected via clinical coding or electronic records/
prescriptions. These data are held by Public health England, 
with whom we had a data-sharing agreement. The data are 
routinely collected National health service hospital data and 
consent is assumed unless the patient specifically withdraws 
this. The data are pseudonymised. Ethical approval was 
obtained from the NHS Health Research Authority 
(16/LO/0503).
One-year survival
Date of death was derived from the Office of National 
Statistics records. The most recent update to this record 
was 21st September 2017, therefore each patient had follow 
up for at least 1-year from their date of diagnosis. 1-year 
survival was defined as survival greater than or equal to 365 
days from the date of diagnosis.
Therapies
An individual was defined as receiving chemotherapy if there 
was a record of administration within 6 months after SCLC 
diagnosis. If no date was present or it was beyond 6 months 
of diagnosis chemotherapy was classed as not given. The 
chemotherapy regimens were grouped according to the first 
chemotherapy drugs that were given except “other”. This 
consisted of drugs given in small quantities e.g., gemcitabine 
+ cisplatin. Chemotherapy regimens that differed to the 
initial prescription were classed as a second-line treatment 
and not were analysed. Chemotherapy regimen was classed 
as “missing” if the administration date was present but 
drug details were not given. Prior to administering the first 
chemotherapy cycle the prescriber has to input the planned 
cycle duration. We used this information for the planned 
cycle duration. We used the consecutive dates recorded for 
when a patient received a chemotherapy dose to determine 
how many cycles of chemotherapy they actually received. 
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Radiotherapy was classed as given if an administration 
date was present after diagnosis. Thoracic radiotherapy 
was stratified by the maximal dose prescribed. For LS-
SCLC this was “radical intent” (≥40 Gy) and “palliative” 
(<40 Gy), whereas for ED-SCLC it was “consolidative” 
(≥40 Gy) and “palliative” (<40 Gy). This dose threshold was 
chosen as it aligned with the Royal College of Radiologists 
recommendations (10). In addition, we conducted a 
sensitivity analysis with a dose threshold at ≥30 Gy for 
radical/consolidative intent. We did not examine whether 
radiotherapy was fractionated to once or twice daily. 
Prophylactic Cranial Irradiation (PCI) was defined as 
radiotherapy given to the skull or with prophylactic intent 
following chemotherapy at 20 or 25 Gy in 5 or 10 fractions 
for people with ED-SCLC and 25 Gy in 10 fractions for 
people with LD-SCLC.
Covariates
Socioeconomic status was calculated from postcode of 
residence (Townsend index of deprivation 1-least deprived 
to 5-most deprived). Performance Status (PS) was classed 
according to World Health Organisation criteria. A patient’s 
pre-treatment Tumour Node Metastases (TNM) records 
were used to classify stage into limited and extensive, similar 
to Veteran Administration Lung Cancer Study Group 
(VALSG) criteria. ED-SCLC was any T or N with M1a/b 
spread (11). Stage was “missing” if TNM was not recorded. 
Charlson index of co-morbidities was categorised as 0, 
1, 2–3 and ≥4. It was calculated from previous diagnoses 
(excluding lung cancer) recorded at hospital admissions up 
to the date of SCLC diagnosis (12,13). Individuals with no 
prior admissions or comorbidities were assigned a score of 0. 
Any variables that had >50% missing data were not included 
in our analysis, e.g., smoking status and forced expiratory 
volume in 1 second. These were assumed to be missing at 
random.
Statistical analysis
All analyses were completed using Stata V15 (Stat Corp, 
TX USA). We described the whole cohort of people 
diagnosed from 1st January 2015 to 21st September 
2016 and performed univariate and multivariable logistic 
regression for the odds of 1-year survival. Our multivariable 
model for 1-year survival included factors that were a 
priori or significant on univariate testing (P≤0.05). These 
factors were age, sex, socioeconomic status, PS, stage, co-
morbidities and chemotherapy. This method reduces the 
effect of selection bias and confounding. We conducted a 
similar sub-analysis in the 2016 population that received 
chemotherapy as our radiotherapy data were limited to 
this time. The multivariable logistic regression model in 
this sub-analysis included receipt of radiotherapy, PCI 
and chemotherapy cycles in addition to the previously 
mentioned factors. We assessed the significance of each 
variable using the likelihood ratio test.
Results
Whole SCLC cohort
There were 6,438 people diagnosed with SCLC whose 
demographics are summarised in Table 1. Approximately 
51.3% (n=3,303) were male and the median age was 70 years 
(IQR 63–76). The majority of individuals had ED-SCLC 
[n=4,264 (66.2%)]. We found that 1,860 (28.9%) people 
survived 1-year. For people with LD-SCLC 1-year survival 
was 53.8% (n=1,068) in contrast to ED-SCLC where this 
was 17.0% (n=725). A total of 1,578 (84.8%) people who 
survived 1-year received chemotherapy. Chemotherapy 
was mostly carboplatin + etoposide (n=1,170) or cisplatin + 
etoposide (n=274).
One-year survival
After adjusting for age, sex, socioeconomic status, PS, 
comorbidities, stage and chemotherapy the multivariable 
analysis showed significant differences in the odds of 
1-year survival by patient factors (Table 1). Males were less 
likely to survive compared with females (males adjusted 
OR 0.70 95% CI: 0.62–0.80). Similarly, increasing age 
was associated with poorer survival (LR trend P=0.01). 
Individuals with worse PS were less likely to survive 1-year 
(PS 2 vs. PS 0 adjusted OR 0.38 95% CI: 0.31–0.48) as were 
people with more co-morbidities (Charlson index ≥4 vs. 
0 adjusted OR 0.62 95% CI: 0.52–0.74). Individuals with 
ED-SCLC were less likely to survive 1-year in comparison 
to LD-SCLC (adjusted OR 0.21 95% CI: 0.19–0.25). 
There was significant variation in 1-year survival by 
receipt of chemotherapy. Individuals who did not receive 
chemotherapy were less likely to survive than those who 
were given carboplatin + etoposide (adjusted OR 0.28 95% 
CI: 0.24–0.33). In contrast, people receiving cisplatin + 
etoposide were more likely to survive (vs. carboplatin + 
etoposide adjusted OR 1.57 95% CI: 1.23–1.99) however, 
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Table 1 Features of patients diagnosed with SCLC and people that survived 1-year from diagnosis with odds ratios for 1-year survival
Factor






P value  
(LR test)n=6,438 % N=1,860 %
Sex
Female 3,135 48.7 1,043 33.3 1 1 0.01
Male 3,303 51.3 817 24.7 0.66 0.59–0.73 0.70 0.62–0.80
Age group
<60 997 15.5 381 38.2 1.48 1.28–1.71 1.25 1.06–1.49 0.01¥
60–79 4,527 70.3 1,335 29.5 1 1
≥80 914 14.2 144 15.8 0.48 0.37–0.54 0.66 0.53–0.82
Townsend Quintile
Least deprived-1 806 12.5 243 30.2 1 1
2 1,117 17.4 334 29.9 0.99 0.81–1.20 1.06 0.83–1.32 0.79
3 1,268 19.7 345 27.2 0.87 0.71–1.05 0.92 0.73–1.15
4 1,516 23.6 444 29.3 0.96 0.80–1.16 0.92 0.74–1.14
Most deprived-5 1,731 26.9 494 28.5 0.93 0.77–1.11 0.92 0.74–1.14
Performance status
0 869 13.5 442 50.9 1 1 <0.01
1 1,918 29.8 742 38.7 0.61 0.52–0.72 0.69 0.57–0.83
2 1,286 20.0 274 21.3 0.26 0.22–0.32 0.38 0.31–0.48
3 806 12.5 65 8.1 0.08 0.06–0.11 0.19 0.14–0.26
4 234 3.6 3 1.3 0.01 0.00–0.04 0.04 0.01–0.14
Missing 1,325 20.6 334 25.2 0.33 0.27–0.39 0.55 0.45–0.68
Charlson comorbidity index
0 1,822 28.3 659 36.2 1 1 <0.01
1 1,306 20.3 514 39.4 1.15 0.99–1.33 1.15 0.97–1.37
2–3 1,227 19.1 340 27.7 0.68 0.58–0.79 0.76 0.63–0.92
≥4 2,083 32.4 347 16.7 0.35 0.30–0.41 0.62 0.52–0.74
Stage
Limited 1,984 30.8 1,068 53.8 1 1 <0.01
Extensive 4,264 66.2 725 17.0 0.18 0.16–0.20 0.21 0.19–0.25
Missing 190 3.0 67 35.3 0.47 0.34–0.64 0.60 0.42–0.85
Chemotherapy
Did not have 
chemotherapy
2,443 37.9 282 11.5 0.21 0.18–0.24 0.28 0.24–0.33 <0.01
Carboplatin + etoposide 3,040 47.2 1,170 38.5 1 1
Cisplatin + etoposide 416 6.5 274 65.9 3.08 2.49–3.83 1.57 1.23–1.99
CAV 24 0.4 3 12.5 0.23 0.07–0.77 0.26 0.07–0.86
Other chemo 83 1.3 26 31.3 0.73 0.46–1.17 0.73 0.43–1.19
Single platinum 273 4.2 45 16.5 0.32 0.23–0.44 0.42 0.30–0.61
Missing drug name 159 2.5 60 37.7 0.97 0.70–1.35 0.86 0.55–1.15
LR, likelihood ratio test. *Adjusted for all other variables in table; ¥, LR test trend. 
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PS, comorbidities and stage were confounders to this. 
Receipt of a single platinum drug conferred poorer survival 
(vs. carboplatin + etoposide adjusted OR 0.42 95% CI: 
0.30–0.61). Socioeconomic status was not associated with 
survival (P=0.79).
Survival following receipt of chemotherapy
We identified 1,761 individuals who were diagnosed in 
2016 and received chemotherapy. Of these, 695 (39.5%) 
survived 1-year. Survival varied considerably by stage, 
hence our results are presented by LD-SCLC and ED-
SCLC separately (combined stage survival can be found in 
Table S1).
Limited stage
The 1-year survival for people with LD-SCLC who 
received chemotherapy was 60.7% (n=381). The following 
results are shown in Table 2. After adjustment for patient, 
tumour, chemotherapy and radiotherapy 1-year survival 
was associated with PS (PS 3–4 vs. PS 0 adjusted OR 0.32 
95% CI: 0.13–0.77). Individuals who were given cisplatin 
+ etoposide were more likely to survive 1-year compared 
with carboplatin + etoposide (adjusted OR 2.09 95% CI: 
1.17–3.74), but PS was a confounding factor. Receipt of 
radical radiotherapy was associated with better survival in 
comparison to not receiving radiotherapy (radical adjusted 
OR 3.32 95% CI: 2.07–5.31). This association remained, 
although less pronounced, when the radical threshold total 
radiotherapy dose was set to 30Gy (vs. nil radiotherapy 
adjusted OR 2.83 95% CI: 1.84–4.34, Table S2). PCI 
augmented the odds of 1-year survival (adjusted OR 2.42 
95% CI: 1.33–4.39). There was no independent association 
between survival and age (P=0.59), sex (P=0.07), co-
morbidity score (P=0.32) and the number of chemotherapy 
cycles administered (P=0.53). We conducted a sub analysis 
of the characteristics of the patients who received 4 vs. 6 
chemotherapy cycles and have included these results in 
Table S3. Both groups were evenly matched.
Extensive stage
Fewer people survived 1-year with ED-SCLC than LD-
SCLC (26.2% n=286). The associated patient factors 
differed to LD-SCLC (shown in Table 3), in particular sex 
(male vs. female adjusted OR 0.53 95% CI: 0.39–0.73) and 
co-morbidity (co-morbidity score ≥4 vs. 0 adjusted OR 
0.64 95% CI: 0.43–0.94). PS was a significant prognostic 
factor (P≤0.01) whereas socioeconomic status (P=0.16) 
and age (P trend=0.30) were not. The odds of survival 
differed by the chemotherapy cycles received. Individuals 
receiving less than the planned amount of cycles (mean 
3 cycles received) were less likely to survive 1-year (vs. 4 
cycles adjusted OR 0.37 95% CI: 0.23–0.61). Similarly, 
people that received a planned amount of chemotherapy 
that was fewer than 4 cycles in length (mean 2 cycles) were 
less likely to survive (vs. 4 cycles adjusted OR 0.27 95% 
CI: 0.09–0.76). Six chemotherapy cycles did not augment 
survival in comparison to 4 (6 vs. 4 adjusted OR 1.34 95% 
CI: 0.81–2.21). We performed a sub analysis of both 4 and 
6 chemotherapy cycle groups and these data can be seen in 
Table S4. On the whole the groups were evenly balanced 
with the exception of PS (6 cycles PS0 21% vs. 4 cycles 
PS0 11%). 
Receipt of PCI was associated with improved 1-year 
survival (received PCI adjusted OR 2.04 95% CI: 1.42–
2.93). However, PCI was mostly offered to individuals who 
were younger [median age for PCI 64 years (IQR 59–70) vs. 
69 years (62–75) no PCI] and had better PS (received PCI 
PS0 23% vs. no PCI PS0 16%). These results can be found 
in Table S5. The median radiotherapy dose prescribed in 
ED-SCLC was 30Gy. A total radiotherapy dose of ≥40 Gy 
threshold both consolidative and palliative radiotherapy 
favoured survival but lacked statistical significance 
(consolidative ≥40 Gy vs. nil adjusted OR 1.88 95% CI: 
0.91–3.87 and palliative vs. no radiotherapy adjusted OR 
1.37 95% CI: 0.99–1.90). Reducing the threshold to ≥30 Gy 
resulted in consolidative radiotherapy being associated with 
improved survival and reduced the odds of survival with 
palliative radiotherapy (consolidative ≥30 Gy vs. nil adjusted 
OR 1.78 95% CI: 1.22–2.59, Table 4). In general, patients 
who received palliative radiotherapy <30 Gy were older 
[median age 68 years (IQR 62–74)] in comparison to those 
who received consolidative radiotherapy ≥30 Gy [65years 
≥30 Gy (IQR 60–72)]. In addition, there was a greater 
proportion of severe comorbidity and males in the group 
who received palliative radiotherapy (<30 Gy) (Charlson 
score ≥4.42% palliative vs. 28% consolidative). Table S6 is a 
table showing the patient demographics.
The chemotherapy regimen was not independently 
associated with survival (P=0.12). However, individuals that 
received single platinum therapy were less likely to survive 
1-year (vs. carboplatin + etoposide adjusted OR 0.36 95% 
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Table 2 Features of patients with limited stage who received chemotherapy and survived 1 year with odds ratios for 1 year survival
Factor
Number surviving 
1 year (n=381 from 
628)
% who survived 









P value  
(LR test)
Sex
Female 220 65.1 1 1 0.07
Male 161 55.5 0.67 0.49–0.92 0.71 0.49–1.03
Age group
<60 78 73.6 1.92 1.20–3.08 1.20 0.69–2.09 0.59¥
60-79 271 59.2 1 1
≥80 32 50.0 0.69 0.41–1.17 0.86 0.47–1.57
Townsend quintile
Least deprived-1 56 65.9 1 1 0.04
2 53 52.5 0.57 0.32–1.04 0.46 0.23–0.92
3 74 61.7 0.83 0.47–1.49 1.03 0.53–2.00
4 98 58.3 0.73 0.42–1.25 0.73 0.39–1.36
Most deprived-5 100 64.9 0.96 0.55–1.67 1.10 0.57–2.10
Performance status
0 110 69.2 1 1 0.02
1 171 65.8 0.86 0.56–1.31 1.04 0.64–1.69
2 63 48.8 0.43 0.26–0.69 0.63 0.36–1.11
3-4 11 28.2 0.18 0.08–0.38 0.32 0.13–0.77
Missing 26 63.4 0.77 0.38–1.58 1.00 0.44–2.27
Charlson comorbidity index
0 128 67.7 1 1 0.32
1 115 66.5 0.94 0.61–1.47 1.19 0.71–2.00
2-3 86 52.8 0.53 0.35–0.82 0.75 0.45–1.24
≥4 52 50.5 0.49 0.30–0.79 0.83 0.47–1.47
Chemotherapy
Carboplatin+ etoposide 254 57.0 1 1 0.01
Cisplatin + etoposide 107 82.3 3.52 2.16–5.73 2.09 1.17–3.74
Other 8 72.7 2.02 0.53–7.70 3.64 0.84–15.66
Single platinum 9 29.0 0.31 0.14–0.67 0.55 0.23–1.34
Missing 3 30.0 0.32 0.08–1.27 0.43 0.08–2.27
Table 2 (continued)
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1 year (n=381 from 
628)
% who survived 









P value  
(LR test)
Chemotherapy cycles received
More than planned (mean 
4 cycles)
10 71.4 0.75 0.21–2.64 0.80 0.19–3.34 0.53
Less than planned (mean 3 
cycles)
169 56.0 0.38 0.22–0.65 0.67 0.37–1.24
4 planned and received 70 76.9 1 1
6 planned and received 80 67.8 0.63 0.34–1.18 0.97 0.48–1.97
Received planned amount 
that was fewer than 4 
cycles (mean 2 cycles)
18 52.9 0.34 0.15–0.78 0.70 0.24–2.04
Missing planned cycles 34 49.3 0.29 0.15–0.57 0.57 0.26–1.23
Received radiotherapy
Did not receive 
radiotherapy 
119 44.2 1 1 <0.01
Radical (≥40 Gy) 197 81.4 5.52 3.69–8.26 3.32 2.07–5.31
Palliative (<40 Gy) 65 55.6 1.58 1.02–2.44 1.53 0.94–2.49
Received PCI
No 261 53.4 1 1 <0.01
Yes 120 86.3 5.52 3.29–9.24 2.42 1.33–4.39
¥, LR test for trend. *Adjusted OR for all other factors in table.
Table 3 Features of patients with extensive stage who received chemotherapy and survived 1 year with odds ratios for 1 year survival
Factor
Number 
surviving 1 year 
(n=286 from 
1,091)
% who survived 









P value  
(LR test)
Sex
Female 166 31.4 1 1 <0.01
Male 120 21.4 0.59 0.45–0.78 0.53 0.39–0.73
Age group
<60 64 29.6 0.88 0.63–1.23 1.10 0.75–1.62 0.30¥
60-79 210 27.1 1 1
≥80 12 12.1 0.33 0.17–0.64 0.59 0.28–1.26
Townsend quintile
Table 3 (continued)
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surviving 1 year 
(n=286 from 
1,091)
% who survived 









P value  
(LR test)
Least deprived- 1 34 28.1 1 1 0.16
2 48 26.4 0.92 0.55–1.53 1.01 0.57–1.80
3 65 27.2 0.96 0.59–1.56 0.98 0.57–1.70
4 81 30.3 1.11 0.69–1.79 1.29 0.76–2.21
Most deprived- 5 58 20.6 0.66 0.41–1.08 0.73 0.42–1.27
Performance status
0 82 42.7 1 1 <0.01
1 125 29.7 0.57 0.40–0.81 0.53 0.36–0.79
2 51 18.4 0.30 0.20–0.46 0.32 0.20–0.51
3-4 12 10.5 0.16 0.08–0.31 0.22 0.10–0.45
Missing 16 18.4 0.30 0.16–0.56 0.29 0.14–0.57
Charlson comorbidity index
0 102 31.4 1 1 <0.01
1 72 38.9 1.39 0.96–2.03 1.76 1.14–2.70
2-3 37 21.0 0.58 0.38–0.90 0.80 0.49–1.30
≥4 75 18.5 0.50 0.35–0.70 0.64 0.43–0.94
Chemotherapy
Carboplatin+ etoposide 254 28.2 1 1 0.12
Cisplatin + etoposide 20 33.9 1.30 0.75–2.28 1.02 0.53–1.95
Other 4 16.0 0.48 0.16–1.43 1.05 0.32–3.52
Single platinum 5 5.3 0.14 0.06–0.35 0.36 0.14–0.92
Missing 3 25.0 0.85 0.23–3.16 2.63 0.50–13.74
Chemotherapy cycles received
More than planned (mean 5 cycles) 6 37.5 1.06 0.36–3.14 1.19 0.36–3.88 <0.01
Less than planned (mean 3 cycles) 91 17.0 0.36 0.23–0.57 0.37 0.23–0.61
4 planned and received 39 36.1 1 1
6 planned and received 117 44.8 1.44 0.91–2.28 1.34 0.81–2.21
Received planned amount that was 
fewer than 4 cycles (mean 2 cycles)
8 13.8 0.28 0.12–0.66 0.27 0.09–0.76
Missing planned cycles 25 22.5 0.51 0.28–0.93 0.46 0.24–0.88
Received radiotherapy
Did not receive radiotherapy 142 20.8 1 1 0.07
Consolidative (≥40 Gy) 21 51.2 4.00 2.11–7.57 1.88 0.91–3.87
Palliative (<40 Gy) 123 33.4 1.91 1.44–2.54 1.37 0.99–1.90
Received PCI
No 191 21.8 1 1 <0.01
Yes 95 44.6 2.90 2.12–3.96 2.04 1.42–2.93
¥, LR test for trend; *Adjusted OR for all other factors in table.
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Table 4 Sensitivity analysis of 1-year survival with different radiotherapy thresholds for extensive stage SCLC

















Received radiotherapy dose threshold ≥40 Gy
Did not receive radiotherapy 142 20.8 1 – 1 – 0.07
Consolidative (≥40 Gy) 21 51.2 4.00 2.11–7.57 1.88 0.91–3.87
Palliative (<40 Gy) 123 33.4 1.91 1.44–2.54 1.37 0.99–1.90
Received radiotherapy dose threshold ≥30 Gy
Did not receive radiotherapy 142 20.8 1 – 1 – <0.01
Consolidative (≥30 Gy) 113 45.2 3.14 2.30–4.28 1.78 1.22–2.59
Palliative (<30 Gy) 31 19.5 0.92 0.60–1.42 0.96 0.59–1.55




We have shown that in all persons diagnosed with 
SCLC sex, age, PS, co-morbidity, stage and receipt of 
chemotherapy are independently associated with 1-year 
survival. For those individuals who go on to receive 
chemotherapy the majority of these factors, with the 
addition of radiotherapy and PCI, but not age, were also 
associated with 1-year survival. Continuing chemotherapy 
to 6 cycles did not increase the odds of 1-year survival in 
comparison to 4.
Strengths
These results provide an up-to date “real  world” 
benchmark of survival for SCLC. 1-year survival is an 
important landmark that is sensitive to treatment effects 
in this aggressive cancer. Observational studies on this 
topic are important to confirm the impact of treatment 
recommendations derived from clinical trials. The complex 
linkage of national data used in our study provides a 
comprehensive picture of the treatments given for SCLC 
and importantly their survival impact to better inform 
treatment decisions for clinicians and patients. These data 
have enabled us to study a large population, which in turn, 
increases the reliability of our results as smaller studies 
are more susceptible to bias, especially due to selection 
of healthier patients. Our data are likely to be reliable 
because there are quality assurance standards applied to the 
collection. Outlier hospitals that fall below 2–3 standard 
deviations from the national audit standard are investigated 
and their data submissions are reviewed. 
Limitations
Our findings may be subject to bias, but these are likely 
to be lower in magnitude than for clinical trials. Some 
variables are prone to immortal time bias, however, many of 
the therapies for SCLC are given within days of diagnosis. 
Hence, the few days survival advantage treated groups 
have is too small a proportion of the 1-year survival to 
significantly bias our results. Similarly, individuals who 
receive treatment may inherently be healthier and fitter 
in comparison to those that do not receive treatment and 
therefore are more likely to survive. However, by adjusting 
for PS and comorbidity this selection bias is lessened and 
in the case of chemotherapy cycles these biases would 
tend to favour survival with 6 cycles over 4, which was not 
demonstrated in this research. The planned chemotherapy 
cycles is an estimated amount and in some patients this 
value may not actually reflect the intended duration as 
those that are less fit are sometimes given chemotherapy 
on a cycle-by-cycle basis. Lastly, our data did not contain 
the time to disease progression. Progression free survival 
is considered an important metric in the evaluation of 
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treatment efficacy but is not the gold standard. Similarly, 
from a patient perspective overall survival may be a more 
important metric. Our method of calculating Charlson 
comorbidity index may overestimate the number of 
people with no comorbidity. These comorbidity data are 
only captured when a patient is admitted to hospital and 
therefore those who are managed as an outpatient may have 
no comorbidity data recorded. However, over 2 thirds of 
people in our dataset had a Charlson score of >0. 
Comparisons with other research
One-year survival
After chemotherapy 1 year survival in our study was 
approximately 26% for ED-SCLC and 60% LD-SCLC. 
In comparison a systematic review that examined one-
year survival from mostly clinical trial research estimated 
1 year survival to be approximately 73% in LD-SCLC and 
38% in ED-SCLC (14). Better survival in clinical trials can 
be explained by selection bias. Indeed most clinical trials 
included patients with PS 0-1 and excluded patients with 
brain metastases whereas our study cohort is unselected in 
this regard.
Patient factors
The associated survival factors identified in our study have 
been identified previously for all people diagnosed with 
SCLC. Females were more likely to survive 1 year than 
males. This finding may relate to greater cardiovascular 
comorbidity in men or delayed presentation. Other 
factors which might be part of this finding are differences 
in drug metabolism between the sexes, whereby females 
have higher circulating concentrations of cytotoxic drug 
metabolites. This has been hypothesised in non-small cell 
lung cancer (15). Similarly, it has been shown that females 
have decreased DNA repair capacity and have higher DNA 
adducts which is relevant to platinum agents as these work 
by inhibiting DNA repair causing further DNA adducts 
triggering cellular apoptosis(16-19) In addition, hormonal 
factors, such as estrogen, may also influence SCLC survival. 
Indeed, when estrogen beta receptors have been identified 
on SCLC cells from males this has been associated with 
better survival (20). 
Age (<70 years) has been shown to confer better 
long term survival in clinical trials as well as real world 
settings (21,22). Indeed, for all patients diagnosed with 
SCLC those who were >79 years old were less likely to 
survive. This is likely a reflection of selection bias due 
to increased comorbidity and treatment nihilism in this 
group of patients i.e., patients are less likely to want 
treatment (23). This hypothesis is supported by our sub 
analysis of patients who received chemotherapy where we 
found that age was not a prognostic factor as comorbidity 
and PS are the main factors that determine whether 
chemotherapy can be administered (24) Survival was not 
considerably different for people with LD-SCLC who were 
PS 0 and 2. This finding is inconsistent with other research 
and is likely a result of small patient numbers not giving 
rise to statistical significance. Indeed overall, we found 
that PS was an independently associated factor with 1-year 
survival. This finding, in addition to stage, is consistent 
with other research and both are used in the Manchester 
prognostic score to estimate 2-year survival (25). Rich et al. 
demonstrated that a worse Charlson Index was associated 
with poorer survival in all stages of SCLC (9).
Chemotherapy
Contrary to our observation of better survival with cisplatin 
+ etoposide in LD-SCLC, a meta-analysis of individual 
patient data has shown no difference between carboplatin 
vs. cisplatin regimens (26). The difference in our results 
may relate to residual selection bias in our cohort. Indeed, 
PS was a strong confounder to receiving chemotherapy, 
suggesting cisplatin was reserved for fitter individuals and 
people receiving concurrent chemo-radiotherapy. Similarly, 
single agent platinum was mostly given to people who had 
worse PS or died before receiving etoposide. In clinical 
practice clinicians may select carboplatin over cisplatin 
when prognosis is short due to a favourable side effect 
profile and convenience of administration. 
PCI
There is strong clinical trial evidence to support PCI 
use in LD-SCLC. A systematic review which included 
mostly LD-SCLC patients from 7 clinical trials found that 
PCI improved survival for people who were in complete 
remission following chemo-radiotherapy for SCLC (27). 
The evidence for the benefit of PCI in ED-SCLC is 
less clear. The European Organisation for Research and 
Treatment of Cancer (EORTC) showed, in 2007, that PCI 
augmented survival for individuals with ED-SCLC who 
had responded to chemotherapy (28). However, this study 
did not report response to chemotherapy or screen for 
asymptomatic brain metastases in all participants. More 
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recently, with the pitfalls of the EORTC study addressed, 
a phase III randomized controlled trial found that PCI 
did not augment survival in a cohort consisting mostly 
of partial chemotherapy responders with ED-SCLC (7). 
Importantly, in our study, patients who received PCI were 
younger and had better PS than those who did not. This 
suggests that in order to achieve this survival benefit careful 
treatment selection is needed. We were unable to ascertain 
the response to chemotherapy before PCI administration. 
However, one can assume that PCI was given to individuals 
who had responded to chemotherapy, in accordance with 
treatment recommendations (1,2).
Radiotherapy
Radiotherapy doses ≥40 Gy augmented the odds of 1-year 
survival but lacked statistical significance in ED-SCLC. 
When reduced to ≥30 Gy these odds decreased for LD-
SCLC and became statistically significant for ED-SCLC. 
This is the resultant effect of 30 Gy doses being used for 
palliative as well as consolidative (life prolonging) treatment, 
in addition it is the median dose prescribed for ED-SCLC. 
The lowest recommended dose by the Royal College of 
Radiologists to treat LD-SCLC is 40 Gy whereas, for ED-
SCLC, 30 Gy can be used as consolidation therapy in 
chemotherapy responders (where the goal is to prolong 
survival) or as palliation of persistent thoracic symptoms 
following chemotherapy (10).
In LD-SCLC the survival benefits of early thoracic 
radiotherapy within the first 2 cycles of chemotherapy were 
established using a schedule of 40 Gy in 15 fractions (29). 
Other studies have also given ≥40 Gy but have investigated 
the delivery of radiotherapy i.e., once vs. twice daily. Turrisi 
et al. found that a total dose of 45 Gy given twice daily 
was superior to once daily (30). This finding was validated 
by the CONVERT trial which demonstrated that a total 
dose of 66 Gy given as 2 Gy in once daily fractions was no 
better, in terms of survival and toxicity, than a total dose of 
45 Gy given in twice daily fractions (31). Nevertheless, both 
these regimens would have been captured in our radical 
radiotherapy group.
For ED-SCLC the addition of thoracic radiotherapy 
in chemotherapy responders has been associated with 
improved survival before (32). A meta-analysis of two 
randomized controlled trials that gave 30 Gy in 10 fractions 
and 54 Gy in 36 fractions found that thoracic radiotherapy 
augmented survival in chemotherapy responders when 
compared no radiotherapy (HR 0.81 95% CI: 0.69–0.96). 
The typical radiotherapy dose given in the palliative dosing 
group was 8 Gy in 1 fraction. We found this had no benefit 
to survival in comparison to not receiving radiotherapy. 
This finding is congruous with the main aim of palliative 
radiotherapy being to reduce symptoms and not prolong 
survival. 
Cycles of chemotherapy
There was no difference between 1-year survival of 4 and 
6 cycles of chemotherapy in our study and the supporting 
evidence in this area is limited. Powell et al. found a 
reduction in the risk of death when more chemotherapy 
cycles were given but was unable to directly compare 4 with 
6 (33). To our knowledge only one study has compared both 
and found no difference in survival for LD-SCLC patients 
and a trend to improved survival with 6 cycles for ED-
SCLC, but this lacked statistical significance (P=0.09) (4) In 
our study, the poorer survival associated with receiving less 
than the planned amount of chemotherapy in ED-SCLC is 
a reflection of underlying treatment selection bias that we 
were unable to adjust for. This would include factors such 
as: disease progression (treatment failure), complications 
and side effects. These factors were not recorded in the data 
we analysed. 
Relevance
Our findings relate to clinical practice and add to the 
evidence base for treatment recommendations. We have 
shown that thoracic radiotherapy (above 40 Gy in LD-
SCLC and 30 Gy in ED-SCLC) and PCI are associated 
with improved 1-year survival and that 6 cycles of 
chemotherapy is no better than 4. This may serve to 
ensure that the treatment emphasis is placed on delivering 
more effective radiotherapy as opposed to extending 
chemotherapy beyond 4 cycles.
Conclusions
This research adds further evidence to factors associated 
with long-term survival in SCLC. Receiving chemotherapy 
is one of the strongest predictors of survival. Balancing 
the survival benefits of chemotherapy with the toxicities 
is important if quality as well as quantity of life is to be 
preserved. We have shown that this may be supported by 
giving 4 cycles of chemotherapy rather than 6, as there 
is no survival advantage from the latter. Appropriate 
administration of radiotherapy and PCI should be 
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encouraged as they provide a survival benefit. In the future, 
advances in SCLC survival may come from adding novel 
therapies to four cycles of optimally delivered chemo and 
radiotherapy and prospective collection of national lung 
cancer data, like that used in this analysis, will be a key 
resource in measuring the success (34).
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Supplementary
Table S1 Features of patients who received chemotherapy and survived 1 year with odds ratios for 1 year survival in all stages
Factor
Number 
surviving 1 year 
(n=695)
% surviving 1 year 









P value  
(LR test)
Sex
Female 404 45.3 1 1
Male 291 33.5 0.61 0.50–0.73 0.61 0.48–0.76 <0.01
Age group
<60 150 45.2 0.79 0.62–1.01 1 0.74–1.35
60-79 498 39.4 1 1
≥80 47 28.3 0.48 0.32–0.72 0.74 0.45–1.21 0.53¥
Townsend quintile
Least deprived- 1 97 44.7 1 1
2 108 37.2 0.73 0.51–1.05 0.8 0.52–1.22
3 142 39.1 0.79 0.57–1.12 1.02 0.68–1.53
4 185 41.3 0.87 0.63–1.21 1.01 0.68–1.50
Most deprived- 5 163 36.8 0.72 0.52–1.00 0.88 0.59–1.31 0.61
Performance status
0 196 54.9 1 1 1
1 307 44.2 0.65 0.50–0.84 0.71 0.53–0.97
2 119 28.9 0.33 0.25–0.45 0.44 0.31–0.63
3 24 16.7 0.16 0.10–0.27 0.29 0.17–0.51
4 1 7.7 0.07 0.01–0.53 0.05 0.00–0.63
Missing 48 34.3 0.43 0.29–0.64 0.46 0.29–0.75 <0.01
Charlson comorbidity index
0 240 45.4 1 1
1 193 52.6 1.34 1.02–1.74 1.42 1.03–1.96
2-3 128 37 0.71 0.54–0.93 0.84 0.60–1.17
≥4 134 25.8 0.42 0.32–0.54 0.75 0.55–1.01 <0.01
Stage
Limited 381 60.7 1 1
Extensive 286 26.2 0.23 0.19–0.29 0.3 0.23–0.39
Missing 28 66.7 1.3 0.67–2.51 1.54 0.72–3.28 <0.01
Chemotherapy
Carboplatin+ etoposide 530 38.4 1 1
Cisplatin + etoposide 133 67.9 3.39 2.46–4.66 1.48 0.99–2.21
CAV 1 20 0.4 0.04–3.60 0.64 0.05–8.59
Other 11 34.4 0.84 0.40–1.76 1.4 0.61–3.24
Single platinum 14 11.1 0.2 0.11–0.35 0.42 0.23–0.79
Missing 6 27.3 0.6 0.23–1.55 1.06 0.33–3.41 0.02
Chemotherapy cycles received
More than planned  
(mean 5 cycles)
16 53.3 0.89 0.41–1.93 0.9 0.36–2.27
Less than planned  
(mean 3 cycles)
275 32 0.37 0.27–0.50 0.47 0.32–0.68
4 planned and received 115 56.1 1 1
6 planned and received 203 52.5 0.86 0.61–1.21 1.22 0.82–1.83
Received planned amount 
excluding 4 & 6 cycles  
(mean 2 cycles)
27 28.4 0.31 0.18–0.52 0.36 0.18–0.72
Missing planned cycles 59 32.1 0.37 0.24–0.56 0.45 0.28–0.74 <0.01
Received radiotherapy
Did not receive radiotherapy 269 27.8 1 1
Radical (≥40 Gy) 233 77.4 8.91 6.58–12.09 2.94 2.04–4.25
Palliative (<40 Gy) 193 39.3 1.69 1.34–2.12 1.43 1.10–1.87 <0.01
Received PCI
No 469 33.6 1 1
Yes 226 61.9 3.21 2.53–4.08 2.08 1.54–2.79 <0.01
¥: LR test for trend. Adjusted OR for all other factors in table.
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Did not receive radiotherapy 119 44.2 1 – 1 – <0.01
Radical (≥40 Gy) 197 81.4 5.52 3.69–8.26 3.32 2.07–5.31
Palliative (<40 Gy) 65 55.6 1.58 1.02–2.44 1.53 0.94–2.49
Received radiotherapy
Did not receive radiotherapy 381 44.2 1 – 1 – <0.01
Radical (≥30 Gy) 236 77.6 4.37 3.15–6.28 2.83 1.84–4.34
Palliative (<30 Gy) 26 47.3 1.13 0.63–2.02 1.31 0.69–2.47
Odds ratios are adjusted for sex, age, social deprivation, PS, comorbidity, receipt of PCI, chemotherapy regimen and cycles.
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Table S3 Characteristics of individuals receiving chemotherapy who had limited stage
Factor
Received 4 cycles Received 6 cycles P value for differences between 
treatment groups (chi2)Number Percentage Number Percentage
Sex
Male 40 44 57 48 0.53
Female 51 56 61 52
Age (median & IQR) 69 (60-75) 67 (60-73) 0.60 (t test)
Performance status
0 29 32 30 25 0.57
1 42 46 52 44
2 13 14 20 17
3 1 1 4 3
Missing 6 7 12 10
Charlson comorbidity score
0 35 38 30 25 0.12
1 26 29 50 42
2-3 21 23 24 20
4 9 10 14 12
Socioeconomic status
1-Least deprived 14 15 18 15 0.89
2 15 16 20 17
3 16 18 21 18
4 25 27 26 22
5-Most deprived 21 23 33 28
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Table S4 Characteristics of individuals receiving chemotherapy who had extensive stage
Factor
Received 4 cycles Received 6 cycles P value for differences between 
treatment groups (chi2)Number Percentage Number Percentage
Sex
Male 49 45 137 52 0.21
Female 59 55 124 48
Age (median + IQR) 68 (62-74) 68 (61-73) 0.24 (t test)
Performance status
0 12 11 55 21 0.03
1 41 38 105 40
2 38 35 61 23
3 10 9 14 5
Missing 7 6 26 10
Charlson comorbidity index
0 38 35 87 33 0.94
1 20 19 46 18
2-3 16 15 37 14
≥4 34 31 91 35
Socioeconomic status
1-Least deprived 17 16 30 11 0.624
2 21 19 47 18
3 24 22 59 23
4 21 19 68 26
5-Most deprived 25 23 57 22
Table S5 Characteristics of individuals receiving PCI who had extensive stage
Factors
Did not receive PCI Received PCI P values for differences between 
treatment groups (chi2)Number Percentage Number Percentage
Sex
Male 455 52 107 50 0.68
Female 423 48 106 50
Age (median & IQR) 69 (62-75) 64 (59-70) <0.01 (t test)
Performance status
0 143 16 49 23 <0.01
1 320 36 101 47
2 238 27 39 18
3 101 12 13 6
Missing 76 9 11 5
Charlson score
0 250 28 75 35 0.08
1 147 17 38 18
2-3 152 17 24 11
≥4 329 37 76 36
Socioeconomic status
Least deprived-1 95 11 26 12 0.95
2 147 17 35 16
3 190 22 49 23
4 218 25 49 23
Most deprived-5 228 26 54 25
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P value for difference 
between treatment 
groups (chi2)
Number % Number % Number % Number %
Sex
Male 204 55 18 44 0.16 104 65 118 47 <0.01
Female 164 45 23 56 55 35 132 53
Age (median 
and IQR)
67 (61-72) 65 (60-73) 0.84 (t test) 68 (62-74) 65 (60-72) 0.02 (t test)
Performance status
0 78 21 10 24 0.15 24 15 64 26 0.07
1 154 42 19 46 71 45 102 41
2 78 21 5 12 32 20 51 20
3 33 9 1 2 18 11 16 6
Missing 25 7 6 15 14 9 17 7
Charlson comorbidity score
0 129 35 13 32 <0.01 52 33 90 36 <0.03
1 61 17 15 37 25 16 51 20
2-3 44 12 9 22 15 9 38 15




37 10 4 10 0.28 15 9 26 10 1.00
2 58 16 6 15 25 16 39 16
3 72 20 13 32 35 22 50 20
4 99 27 12 29 44 28 67 27
Most 
deprived-5
102 28 6 15 40 25 68 27
